The AseBio 2020 Report shows the great leap of Spanish biotechnology in the year of the pandemic.
In 2018, the biotechnology sector invested nearly €770 million in R&D, 71% from biotech companies.
Biotechnology companies have had an impact on the Spanish economy of almost 7,000 million euros (0.7% of GDP) and have generated 92,384 jobs.
In 2017, financial operations in the Spanish biotechnology sector reached 149 million euros.
This edition of the annual report introduces a new methodology for calculating the economic impact of the sector.
The data in this report shows that most of the ratios in the sector have grown: turnover, employment, investment in R&D.
In 2013 the sector has perceived the crisis, with a decrease in the number of biotech companies and companies with biotechnological activities.
The latest advances in molecular biology have allowed us to identify a whole series of biomarkers that have meant a very significant improvement in the diagnosis and prognosis of diseases.
During 2012 the ASEBIO associated entities had launch a total of 132 products or services; 94 were direct to the field of human health, 30 to the agri-food field, 18 were industrial processes and 16 to animal health.
In 2011, a total of 112 alliances were registered, 63% were carried out with another biotech company, 46% with public entities and 38% with a user company.
In 2009 the national biotech sector reached 1,095 companies with activities in biotechnology, of which 399 are dedicated exclusively to biotechnology. The personnel employed amounted to 148,648 and the turnover to € 53,152 MM.
Despite the economic crisis, in 2008 the biotechnology sector had a turnover of more than 31,100 million euros and employed 108,374 people, with year-on-year growth of 18.9 and 4.3% respectively.
Approximately 30% of ASEBIO companies exported a total of € 108 MM. Spanish biotech companies export both products and services linked to R&D, especially in the area of Biomedicine and with a certain presence in the agri-food sector.